Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma

BACKGROUND: Treatment for Cutaneous T Cell Lymphoma (CTCL) is generally not curative. Therefore, selecting therapy that is effective and tolerable is critical to clinical decision-making. Histone deacetylase inhibitors (HDACi), epigenetic modifier drugs, are commonly used but effective in only ~30%...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrews, Jared M., Schmidt, Jennifer A., Carson, Kenneth R., Musiek, Amy C., Mehta-Shah, Neha, Payton, Jacqueline E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711861/
https://www.ncbi.nlm.nih.gov/pubmed/31358475
http://dx.doi.org/10.1016/j.ebiom.2019.07.053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711861/
https://www.ncbi.nlm.nih.gov/pubmed/31358475
http://dx.doi.org/10.1016/j.ebiom.2019.07.053

Ejemplares similares